General MedicationsINTRAVENOUSStandard
IBUPROFEN LYSINE
IBUPROFEN LYSINE
Standard Dose
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview IBUPROFEN LYSINE is listed in Drugs@FDA under application 202402 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient IBUPROFEN LYSINE Form and strength INJECTABLE;INTRAVENOUS - EQ 20MG BASE/2ML (EQ 10MG BASE/ML) Sponsor XGEN PHARMS Submission history Latest submission status date: 2024-07-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview IBUPROFEN LYSINE is listed in Drugs@FDA under application 202402 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IBUPROFEN LYSINE Form and strength INJECTABLE;INTRAVENOUS - EQ 20MG BASE/2ML (EQ 10MG BASE/ML) Sponsor XGEN PHARMS Submission history Latest submission status date: 2024-07-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.